W. R. Berkley Corporation (WRB)

FairStock Score: 64/100 — STEADY

Key Financials

Strengths

• Strong free cash flow generation of $3.4B with 3.4% FCF yield supports dividends and buybacks
• Solid 19.7% ROE demonstrates above-average capital efficiency for insurance sector
• Low leverage (D/E: 0.32) and conservative balance sheet reduce financial distress risk
• Diversified underwriting across commercial, specialty, and reinsurance segments reduces concentration risk
• Consistent Q4 2025 performance with 12.1% net margin shows operational execution

Concerns

• Valuation grossly disconnected from intrinsic value with -165% margin of safety and P/B of 2.56
• Disappointing ROCE of 3.66% indicates capital deployment below cost of capital despite solid ROE
• Piotroski F-Score of 5/9 signals deteriorating financial quality year-over-year
• Altman Z-Score of 0.96 approaches distress zone despite appearing solvent on surface
• Reinsurance segment exposes company to catastrophic tail risks that quarterly metrics obscure

AI Analysis

W. R. Berkley presents a moderately attractive insurance operator, though not without reservations. The company demonstrates solid operational performance with a 12.1% net margin in Q4 2025 and respectable 19.7% ROE, suggesting management deploys capital with reasonable efficiency. The $3.4B free cash flow yield of 3.4% indicates genuine cash generation capability—essential for insurance businesses that must maintain underwriting discipline. However, I must temper my enthusiasm. The Graham Number of $25.57 versus a market price of $67.86 reveals a substantial valuation gap of 165%. This is not margin of safety; this is speculative territory. The P/B ratio of 2.56 seems elevated for an insurance carrier, even one with decent returns. More troubling is the Piotroski F-Score of 5/9—below the quality threshold I prefer—and an Altman Z-Score of 0.96, suggesting potential financial stress despite seemingly adequate balance sheet metrics. The insurance industry's cyclical nature demands scrutiny. While WRB's low beta of 0.34 suggests stability, the ROCE of 3.66% is disappointing and questions whether this capital actually earns its cost. The modest leverage (D/E: 0.32) is prudent, but reinsurance exposure introduces tail risks I cannot easily quantify from quarterly metrics. WRB is competently managed in a reasonable business, but valuation disconnects from intrinsic value. I'd prefer waiting for a meaningful pullback—ideally toward the Graham Number—before committing capital. Quality matters less when price is unreasonable.

Bull Case

WRB's combination of 19.7% ROE, robust $3.4B annual free cash flow, and conservative 0.32 leverage positions it as a reliable comppounder if underwriting discipline remains intact. Management's ability to grow premium volume while maintaining discipline could drive sustained mid-to-high single-digit returns as the insurance cycle normalizes.

Bear Case

Valuation at $67.86 prices in perfection when the Piotroski F-Score decline and Z-Score proximity to distress suggest operational headwinds. Reinsurance exposure to catastrophic events combined with potential underwriting cycle deterioration could compress margins and destroy shareholder value from current levels.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer